2023-08-14T22:00:18+00:00 2022-09-30 346565596 ERNST & YOUNG US LLP 18101 VON KARMAN AVENUE IRVINE CA 92612 990 2021-10-01 753065445 THE TRANSLATIONAL GENOMICS RESEARCH INSTITUTE TRAN 6023438400 445 N 5TH STREET 600 PHOENIX AZ 85004 JEFFREY M TRENT PHD BOARD MEMBER/PRES/SCIENCE DIR. 2023-08-14 true MANUEL ESTRADA 999009999 Kara Adams P00023315 9497942300 2023-08-09 2021 2023-04-26 12:10:37Z JEFFREY M TRENT PHD 445 N 5TH STREET 600 PHOENIX AZ 85004 57558632 false X WWW.TGEN.ORG X 2002 AZ PLEASE SEE SCHEDULE O 12 10 450 42 0 0 36277806 33269986 25808862 14701502 68189525 3778567 45411597 -3960559 175687790 47789496 328217 0 40026832 41065789 0 0 59165763 33110939 99192595 74504945 76495195 -26715449 224233974 174203210 69704038 57234236 154529936 116968974 X Please see Schedule O false false 7144666 0 819775 Please see Schedule O 6457459 0 5454862 Please see Schedule O 4437437 0 1958985 Please see Schedule O 31824392 328217 6467880 JUNE 26, 2022, MARKED THE 20TH ANNIVERSARY OF TGEN'S LAUNCH. WHAT BEGAN WITH TEMPORARY LABORATORY AND ADMINISTRATIVE SPACE AND A HANDFUL OF EMPLOYEES HAS GROWN INTO AN INSTITUTE WITH OVER 350 EMPLOYEES, MULTIPLE LOCATIONS, HUNDREDS OF COLLABORATIONS AROUND THE WORLD, NUMEROUS GROUNDBREAKING STUDIES, AND NEARLY 20 SPIN-OUT COMPANIES. TODAY, OUR CAPACITY TO UNDERSTAND AND LEVERAGE INFORMATION FROM THE HUMAN GENOME HAS NEVER BEEN GREATER. TGEN'S ABILITY TO BRING EMERGING NEW METHODS FOR INTERROGATING A PATIENT'S GENOME INTO THE CLINICAL CARE OF PATIENTS, THE REVOLUTION IN FASTER AND LOWER-COST WAYS OF CANCER DETECTION AND THE PATHS THAT REACH THE URBAN, THE RURAL AND MORE DIVERSE POPULATIONS, HAS NEVER BEEN GREATER. THE SEQUENCE COST PER-PATIENT OVER THE PAST DECADE HAS DROPPED 100-FOLD. THIS MEANS TGEN CAN SEQUENCE MORE PATIENTS, OR SEQUENCE A PATIENT AGAIN, TO UNDERSTAND HOW THEIR DISEASE IS PROGRESSING. AS PART OF A NATIONAL HEALTH SYSTEM, THIS HELPS DRIVE RESEARCH DISCOVERY, NEW METHODS FOR EARLY DETECTION, AND MORE CLINICAL TRIALS. SEQUENCING ACCURACY HAS ALSO IMPROVED 100-FOLD. THIS INCREASED ACCURACY MEANS TGEN CAN DETECT CANCER EARLIER - PERHAPS IN ITS INFANCY - WHICH LEADS TO IMPROVED SCREENING, POST-TREATMENT MONITORING AND BIOPSIES WITH A LOW PERCENTAGE OF TUMOR PRESENT. THIS ALSO ALLOWS US TO EXPAND GENOMIC TESTING INTO MORE CANCER TYPES. WE'RE ALSO CREATING BETTER REFERENCE GENOMES, ESPECIALLY IN UNDERSERVED POPULATIONS. HAVING BETTER REFERENCES MEANS A BETTER UNDERSTANDING OF WHICH CHANGES IN THE GENOME ARE SIGNIFICANT AND TO WHICH POPULATION. 31824392 328217 6467880 49863954 true true false true false false false true true true false true true true true false true false false true false false false false false false true false true false false false true false false false false false false false false true true true true false false true 103 0 true 450 true false false false false false false false false false false true false X 12 10 false false false false true true true true false false false true true true true true true true true false X TRACY KARNS 6023438415 445 N 5TH STREET SUITE 600 PHOENIX AZ 85004 JEFFREY M TRENT PHD BOARD MEMBER/PRES/SCIENCE DIR. 39.0 1.0 X X 0 1756429 258536 ROBERT W STONE BD & VICE CHRM/COH CEO & PRES. 1.0 60.0 X X 0 3468047 645461 WILLIAM J POST BOARD MEMBER/CHAIRMAN 1.0 3.0 X X 0 0 0 ANTHONY SCOTT BOARD MEMBER 1.0 0 X 0 0 0 BENNETT DORRANCE BOARD MEMBER 1.0 1.0 X 0 0 0 DAVID J GULLEN MD BOARD MEMBER 1.0 0 X 0 0 0 KAREN QUINTOS BOARD MEMBER 1.0 0 X 0 0 0 MARILYN QUAYLE BOARD MEMBER 1.0 0 X 0 0 0 PAMELA KEHALY BOARD MEMBER 1.0 0 X 0 0 0 RICHARD SILVERMAN BOARD MEMBER 1.0 0 X 0 0 0 SHARON HARPER BOARD MEMBER 1.0 0 X 0 0 0 TERRY PEETS BOARD MEMBER 1.0 0 X 0 0 0 CRISTIN O'CALLAHAN SECRETARY/COH GENERAL COUNSEL 1.0 60.0 X 0 574556 121560 GREGORY D SCHETINA SECRETARY/COH GENERAL COUNSEL (PT YR) 1.0 60.0 X 0 1266856 184060 JAMES LOWEY CHIEF INFORMATION OFFICER 40.0 0 X 432851 0 22299 JENNIFER A PARKHURST TREASURER/COH CFO 1.0 60.0 X 0 1907352 274536 MANUEL ESTRADA CFO/ASSISTANT TREASURER 39.0 1.0 X 549445 0 18898 STEPHANIE MCRAE GENERAL COUNSEL/ASST SECRETARY 40.0 0 X 535094 0 16353 TERESA BURLESON CHIEF OPERATING OFFICER 39.0 1.0 X 1071675 0 24475 DANIEL VON HOFF PHYSICIAN IN CHIEF 40.0 0 X 954505 0 22755 KENDALL JENSEN DEPUTY DIR. OF RESEARCH RES. 40.0 0 X 426683 0 23791 MICHAEL BERENS DEPUTY DIRECTOR OF RESEARCH 40.0 0 X 578935 0 29175 SUNIL SHARMA DEPUTY DIR OF CLINIC. SCIENCES 40.0 0 X 720379 0 23715 CHERYL BABO GENERAL COUNSEL, ASSOCIATE 40.0 0 X 349786 0 25389 DAVID HAWORTH PRESIDENT, VIDIUM 40.0 0 X 439713 0 25719 EDWARD SHAFFER VP, TECHNOLOGY STRATEGY AND INNOVATION 40.0 0 X 330117 0 16043 GALEN PERRY SR. VP OF MKTG & COMMUNICATION 40.0 0 X 304957 0 26893 NICHOLAS SCHORK PROFESSOR 40.0 0 X 514470 0 17475 Cornelis Van den Berg FORMER OFFICER 0.0 60.0 X 0 768960 78516 TIMOTHY MCDANIEL SR. VP OF EMERG. OPP 40.0 0 X 571482 0 13348 7780093 9742200 1868998 118 false true false GIRIKON LLC 15433 N TATUM BLVD SUITE 105 PHOENIX AZ 85032 CONSULTING SERVICES 654715 PRICEWATERHOUSECOOPERS LLP PO BOX 514038 LOS ANGELES CA 900514038 CONSULTING SERVICES 245000 FIRSTSTRATEGIC 300 W CLARENDON AVE SUITE 460 PHOENIX AZ 85013 CONSULTING SERVICES 216000 ERNST & YOUNG LLP PO BOX 846793 LOS ANGELES CA 90084 PROFESSIONAL SERVICES 190000 MUHAMMED MURTAZA 1002 WINDING WAY MIDDLETON WI 53562 PROFESSIONAL SERVICES 150000 5 0 0 0 11704667 15699692 5865627 33269986 RESEARCH CONTRACTS 541711 14701502 14701502 0 0 0 0 0 0 14701502 634120 634120 3348431 7308990 -3960559 0 -3960559 -3960559 5330319 274274 2460146 0 2870173 274274 3144447 0 0 3144447 0 0 0 0 0 47789496 14701502 0 -181992 X 328217 328217 0 0 0 0 0 0 5065632 2810249 2255383 0 0 0 30221626 18433749 11787877 0 711655 382493 329162 0 2731300 1646050 1085250 0 2335576 1410000 925576 0 0 0 0 581550 279144 302406 0 470521 9410 461111 0 129600 0 129600 0 0 0 0 0 0 0 8108564 6246691 1861873 0 1351196 1013397 337799 0 10793516 10248149 545367 0 2574453 2081556 492897 0 0 0 0 0 588302 194140 394162 0 311205 144065 167140 0 0 0 0 0 388376 70409 317967 0 118254 79230 39024 0 6061827 3962768 2099059 0 389621 88837 300784 0 LOSS ON ASSET ACQUISITION 500000 0 500000 0 RECRUITMENT 268344 201258 67086 RELOCATION 151196 113397 37799 0 BAD DEBT EXPENSE 92400 92400 0 0 232014 28345 203669 0 74504945 49863954 24640991 0 0 0 0 0 129097377 15119862 12190648 10356014 9007792 9237581 283706 409085 75000 25000 0 0 0 0 2188666 1847445 84960447 28759864 51820296 56200583 0 0 61414092 8761703 8276723 10808786 11316825 224233974 174203210 18831065 9093772 2132540 1909599 0 50000 50000 0 47372761 45095201 50000 0 1267672 1085664 69704038 57234236 X 146224427 110923289 8305509 6045685 154529936 116968974 224233974 174203210 -26715449 -10845513 0 X false true X true true true X 31879587 62343578 54124639 36879938 33269986 218497728 0 0 31879587 62343578 54124639 36879938 33269986 218497728 3125684 215372044 4179409 3155820 3056541 52873472 3982551 67247793 0 5677144 0 0 0 0 5677144 291422665 104698442 0.7390 0.7201 X Schedule A, Part II, Line 10 Other Income DESCRIPTION - OTHER, COLUMN A - 5677144.0, COLUMN B - , COLUMN C - , COLUMN D - , COLUMN E - , COLUMN F - 5677144.0; RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED false false false false false false false false true 129600 129600 false Schedule C, Part II-B, Line 1 DETAILED DESCRIPTION OF THE LOBBYING ACTIVITY THE TRANSLATIONAL GENOMICS RESEARCH INSTITUTE (TGEN) USES A THIRD PARTY COMMUNICATIONS AND PUBLIC AFFAIRS FIRM TO COORDINATE LOBBYING EFFORTS ON BEHALF OF TGEN THROUGH COMMUNICATIONS TO LOCAL GOVERNMENT, LEGISLATIVE AND FEDERAL OFFICIALS AND COMMUNITY LEADERS ON TGEN ACTIVITIES. false true X 6833524 171950 -815957 577565 5611952 6696827 173542 517109 553954 6833524 6186285 378481 419824 287763 6696827 5088052 1373720 227248 502735 6186285 5355690 75833 182488 525959 5088052 0.0 0.0111 0.9889 false true true 47657151 8677006 38980145 4194360 2273003 1921357 28839087 15619728 13219359 4269849 2190127 2079722 56200583 COH LT Investment 61414092 F 61414092 DUE FROM RELATED ORGANIZATIONS 10231161 EMPLOYEE 457 (B) PLAN ASSETS 1085664 11316825 DUE TO EMPLOYEE 457 (B) PLAN 1085664 1085664 X Schedule D, Part IV, Line 2b Explanation of escrow agreement ASSET PURCHASE HOLDBACK Schedule D, Part V, Line 4 Intended uses of endowment funds TGEN FOUNDATION CLASSIFIES AS PERMANENTLY RESTRICTED NET ASSETS (1) THE ORIGINAL VALUE OF THE GIFT DONATED TO THE PERMANENT ENDOWMENT, (2) THE ORIGINAL VALUE OF SUBSEQUENT GIFTS DONATED TO THE PERMANENT ENDOWMENT, AND (3) ACCUMULATIONS TO THE PERMANENT ENDOWMENT MADE IN ACCORDANCE WITH THE DIRECTION OF THE APPLICABLE DONOR GIFT INSTRUMENT. TGEN FOUNDATION HAS A TEMPORARILY RESTRICTED ASSET WHICH HAS BEEN DESIGNATED TO SUPPORT SUMMER INTERNS EACH YEAR AT TGEN. TGEN FOUNDATION'S POLICY FOR APPROPRIATING THE DISTRIBUTION OF ITS SUMMER INTERNSHIP PROGRAM ENDOWMENT HAS BEEN DESIGNED TO SUPPORT A GRANT TO TGEN FOR AN INTERN EACH YEAR FOR 25 YEARS. THE FOUNDATION CONSIDERED THE LONG-TERM EXPECTED RETURN ON ITS ENDOWMENT. TGEN FOUNDATION HAS A RESTRICTED ASSET FOR THE ESTABLISHMENT OF AN ENDOWED CHAIR IN BRAIN CANCER RESEARCH. TGEN FOUNDATION ALSO HAS A RESTRICTED ASSET WHICH ALLOWS THEM TO USE ANY INVESTMENT INCOME FOR OPERATING EXPENSES. Schedule D, Part X, Line 2 FIN 48 (ASC 740) footnote THE TRANSLATIONAL GENOMICS RESEARCH INSTITUTE AND ITS AFFILIATES ARE INCLUDED IN THE CONSOLIDATED AUDITED FINANCIAL STATEMENTS OF CITY OF HOPE (FEIN: 95-3435919, A RELATED TAX-EXEMPT ENTITY) WHICH INCLUDES CITY OF HOPE, CITY OF HOPE NATIONAL MEDICAL CENTER, THE MEDICAL FOUNDATION, BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE, THE TRANSLATIONAL GENOMICS RESEARCH INSTITUTE AND ITS AFFILIATES, SOUTHERN CALIFORNIA RADIATION ONCOLOGY, LLC, ACCESSHOPE, LLC, CITY OF HOPE AUXILIARIES (AUXILIARIES) AND COH HOLDCO, INC. BELOW IS THE FOOTNOTE ADDRESSING THE ORGANIZATION'S LIABILITY FOR UNCERTAIN TAX POSITIONS. ASC 740, INCOME TAXES, CLARIFIES THE ACCOUNTING FOR INCOME TAXES BY PRESCRIBING A MINIMUM RECOGNITION THRESHOLD THAT A TAX POSITION IS REQUIRED TO MEET BEFORE BEING RECOGNIZED IN THE FINANCIAL STATEMENTS. ASC 740 ALSO PROVIDES GUIDANCE ON DE-RECOGNITION, MEASUREMENT, CLASSIFICATION, INTEREST AND PENALTIES, DISCLOSURE, AND TRANSITION. THE GUIDANCE CONTAINED IN ASC 740 IS APPLICABLE TO PASS-THROUGH ENTITIES AND TAX-EXEMPT ORGANIZATIONS. CITY OF HOPE HAS NO SIGNIFICANT UNCERTAIN TAX POSITIONS OR TAX LIABILITY FOR TAX BENEFITS, INTEREST, OR PENALTIES ACCRUED AS OF SEPTEMBER 30, 2022 OR 2021. East Asia and the Pacific 0 0 Program Services RESEARCH SERVICES 11505 Middle East and North Africa 0 0 Program Services RESEARCH SERVICES 108542 Europe (Including Iceland and Greenland) 0 0 Program Services RESEARCH SERVICES 293702 North America (Canada & Mexico only) 0 0 Program Services RESEARCH SERVICES 192687 South America 0 0 Program Services RESEARCH SERVICES 7266 South Asia 0 0 Program Services RESEARCH SERVICES 178458 0 0 0 0 0 0 792160 0 792160 false false false false false false Schedule F, Part I, Line 3 Method used to account for expenditures on org's financial statements EAST ASIA AND THE PACIFIC-Accrual; EUROPE (INCLUDING ICELAND AND GREENLAND)-Accrual; MIDDLE EAST AND NORTH AFRICA-Accrual; NORTH AMERICA (CANADA & MEXICO ONLY)-Accrual; SOUTH AMERICA-Accrual; SOUTH ASIA-Accrual true CITY OF HOPE NATIONAL MEDICAL CENTER 1500 EAST DUARTE ROAD DUARTE CA 91010 951683875 501(c)(3) 328217 Project Support 1 0 Schedule I, Part I, Line 2 Procedures for monitoring use of grant funds. TGen monitors its grants to ensure such grants are used for proper purposes via regular financial reviews with the grantee. Progress against goals is also reviewed with the grantees regularly. false true false false false false false true false ROBERT W STONE BD & VICE CHRM/COH CEO & PRES. 0 1605123 0 1445927 0 416997 0 605712 0 39749 0 4113508 0 428637 JEFFREY M TRENT PHD BOARD MEMBER/PRES/SCIENCE DIR. 0 820853 0 696314 0 239262 0 226975 0 31561 0 2014965 0 175135 Cornelis Van den Berg FORMER OFFICER 0 461556 0 191460 0 115944 0 52652 0 25864 0 847476 0 32156 TERESA BURLESON CHIEF OPERATING OFFICER 587396 0 483037 0 1242 0 11311 0 13164 0 1096151 0 103846 0 MANUEL ESTRADA CFO/ASSISTANT TREASURER 368419 0 178550 0 2475 0 5625 0 13274 0 568343 0 0 0 JAMES LOWEY CHIEF INFORMATION OFFICER 299616 0 131501 0 1734 0 11562 0 10737 0 455150 0 0 0 STEPHANIE MCRAE GENERAL COUNSEL/ASST SECRETARY 351772 0 161500 0 21822 0 3265 0 13088 0 551447 0 0 0 CRISTIN O'CALLAHAN SECRETARY/COH GENERAL COUNSEL 0 351864 0 124716 0 97976 0 72964 0 48596 0 696116 0 0 JENNIFER A PARKHURST TREASURER/COH CFO 0 820668 0 673624 0 413060 0 228800 0 45736 0 2181888 0 371032 GREGORY D SCHETINA SECRETARY/COH GENERAL COUNSEL (PT YR) 0 620040 0 474756 0 172060 0 136796 0 47264 0 1450916 0 121216 TIMOTHY MCDANIEL SR. VP OF EMERG. OPP 253148 0 303000 0 15334 0 5568 0 7781 0 584830 0 0 0 MICHAEL BERENS DEPUTY DIRECTOR OF RESEARCH 421455 0 133637 0 23842 0 16332 0 12843 0 608109 0 0 0 KENDALL JENSEN DEPUTY DIR. OF RESEARCH RES. 331429 0 94013 0 1242 0 8226 0 15564 0 450474 0 0 0 SUNIL SHARMA DEPUTY DIR OF CLINIC. SCIENCES 568557 0 130000 0 21822 0 8833 0 14882 0 744095 0 0 0 DANIEL VON HOFF PHYSICIAN IN CHIEF 850079 0 100000 0 4426 0 10162 0 12593 0 977260 0 50000 0 CHERYL BABO GENERAL COUNSEL, ASSOCIATE 247906 0 99000 0 2880 0 22647 0 2742 0 375175 0 0 0 DAVID HAWORTH PRESIDENT, VIDIUM 365471 0 73000 0 1242 0 11562 0 14158 0 465432 0 0 0 GALEN PERRY SR. VP OF MKTG & COMMUNICATION 244057 0 57428 0 3473 0 11467 0 15427 0 331851 0 0 0 NICHOLAS SCHORK PROFESSOR 439822 0 72327 0 2322 0 11536 0 5940 0 531946 0 0 0 EDWARD SHAFFER VP, TECHNOLOGY STRATEGY AND INNOVATION 268244 0 60631 0 1242 0 11186 0 4857 0 346160 0 0 0 Schedule J, Part I, Line 3 Arrangement used to establish the top management official's compensation THE PRESIDENT OF TGEN IS COMPENSATED BY ITS RELATED ORGANIZATION, CITY OF HOPE, WHICH ALSO DETERMINES THE METHODS FOR ESTABLISHING COMPENSATION. Schedule J, Part I, Line 4b Supplemental nonqualified retirement plan THE CITY OF HOPE HAS A NON-QUALIFIED SECTION 457(F) EXECUTIVE SUPPLEMENTAL ACCUMULATION PLAN THAT IS DESIGNED AND MAINTAINED TO PROVIDE A SELECT GROUP OF MANAGEMENT OR HIGHLY COMPENSATED EMPLOYEES WITH DEFERRED COMPENSATION. THE PLAN VESTS AFTER THREE (3) FISCAL YEARS OF SERVICE AND THE VESTED TOTALS ARE INCLUDED IN SCHEDULE J, PART II, COLUMN B (III). PRIOR TO VESTING, THE ANNUAL AMOUNTS ARE INCLUDED IN SCHEDULE J, PART II, COLUMN C. PURSUANT TO THE PLAN DOCUMENT, VESTED PARTICIPANTS ARE ENTITLED TO WITHDRAW FROM THEIR VESTED ACCOUNT AN AMOUNT EQUAL TO THE FEDERAL, STATE, LOCAL AND FICA TAXES THEY OWE. THESE AMOUNTS ARE REMITTED TO THE APPROPRIATE TAXING AUTHORITIES ON BEHALF OF THE PARTICIPANTS. DURING CALENDAR YEAR 2021 THE FOLLOWING INDIVIDUALS WITHDREW THE REFERENCED AMOUNTS TO COVER SUCH TAXES: ROBERT W. STONE $43,349 GREGORY D. SCHETINA $12,186 Cornelis Van Den Berg $15,942 THESE AMOUNTS HAVE BEEN INCLUDED IN THE PARTICIPANTS INCOME ON SCHEDULE J, PART II, COLUMN B(III). Schedule J, Part I, Line 7 Non-fixed payments SOME OF TGEN'S OFFICERS AND KEY EMPLOYEES LISTED IN PART VII WERE PAID BONUSES WHICH WERE BASED ON ACCOMPLISHMENTS OF SPECIFIC MILESTONES AND/OR PERFORMANCE METRICS, AS APPROVED BY THE TGEN BOARD OF DIRECTORS. Schedule J, Part II SCHEDULE J, PART II SOME OF TGEN'S OFFICERS AND KEY EMPLOYEES LISTED IN PART VII HAVE RETENTION AGREEMENTS THROUGH 2021 AND 2020. AMOUNTS ACCRUED BY TGEN DURING CALENDAR YEAR 2021 UNDER THESE AGREEMENTS HAVE BEEN REPORTED IN SCHEDULE J, PART II, COLUMN (C) AS DEFERRED COMPENSATION. KENDALL JENSEN EMPLOYEE RELOCATION ASSISTANCE X 250000 25000 false true true 25000 Form 990, Part I, Line 1 THE TRANSLATIONAL GENOMICS RESEARCH INSTITUTE (TGEN) IS A NONPROFIT BIOMEDICAL RESEARCH INSTITUTE FOCUSED ON DEVELOPING EARLIER AND SMARTER TREATMENTS BY EMPLOYING INNOVATIVE ADVANCES ARISING FROM THE HUMAN GENOME PROJECT AND APPLYING THEM TO THE DEVELOPMENT OF DIAGNOSTICS, PROGNOSTICS AND THERAPIES FOR CANCER, NEUROLOGICAL DISORDERS, DIABETES AND OTHER COMPLEX DISEASES. Form 990, Part III, Line 4a NEUROGENOMICS THE NEUROGENOMICS DIVISION RESEARCH PROGRAMS SPAN ALL AGES, FROM DEVELOPMENTAL DISORDERS EARLY IN LIFE, THROUGH DISEASES OF ADULTHOOD SUCH AS NEURONAL DEGENERATION INCLUDING ALS, ALZHEIMER'S DISEASE AND PARKINSON'S DISEASE AS WELL AS STROKE AND NEUROTRAUMA SUCH AS FROM CONCUSSION. OUR FIRST GOAL IS TO IMPROVE THE ABILITY TO DIAGNOSE NEUROLOGICAL DISEASE BEFORE IT STRIKES BY UNDERSTANDING THE INDIVIDUAL GENETIC AND EPIGENETIC VARIATION BETWEEN INDIVIDUALS. BECAUSE THESE DISEASES IMPACT SO MANY LIVES AROUND THE WORLD EITHER DIRECTLY (BY HAVING A DISEASE), OR INDIRECTLY (BY CARING FOR A LOVED ONE WITH THE DISEASE), THE SECOND GOAL CENTERS ON THE DEVELOPMENT OF NEW DRUG THERAPIES THAT SPECIFICALLY UTILIZE AN INDIVIDUAL'S GENETIC BACKGROUND. OVER THE PAST 20 YEARS, OUR INVESTIGATORS HAVE BEEN AWARDED DOZENS OF LARGE FEDERAL AND FOUNDATION GRANTS, AND DEVELOPED A RESEARCH CLINIC FOCUSED ON DIRECTLY INTERACTING WITH THE COMMUNITY AND PATIENTS IN THE AREA OF PRECISION MEDICINE. Form 990, Part III, Line 4b PATHOGEN AND MICROBIOME THE PATHOGEN AND MICROBIOME DIVISION IS FOCUSED ON DEVELOPING AND TRANSLATING MICROBIAL GENOMIC DISCOVERIES INTO APPLICATION TO ADVANCE HUMAN HEALTH IN THE AREAS OF CLINICAL MEDICINE, PUBLIC HEALTH AND BIODEFENSE. THE DIVISION SEEKS TO ADVANCE OUR UNDERSTANDING OF MULTI-DRUG RESISTANT INFECTIONS, DEVELOP NOVEL GENOTYPING TECHNIQUES FOR GENOMIC EPIDEMIOLOGY AND MICROBIAL FORENSICS, FUNGAL EPIDEMIOLOGY AND PHYLOGENETICS, UNDERSTAND THE RELATIONSHIP OF MICROBES TO HUMAN HEALTH AND DISEASE, AND THROUGH THE TGEN NORTH CLIA LAB OFFER PCR AND SEROLOGY TESTING FOR SARS-COV-2. A MAJOR EMPHASIS IS ON ADAPTING AND ADVANCING NEXT-GENERATION SEQUENCING TOOLS FOR INFECTIOUS DISEASE RESEARCH AND HEALTHCARE SUCH AS DIAGNOSTIC TESTS TO CHARACTERIZE AND TRACK HOSPITAL ACQUIRED INFECTIONS, WITH AN EMPHASIS ON ANTIBIOTIC RESISTANCE, ALLOWING PHYSICIANS TO PROVIDE PERSONALIZED THERAPY AND CONTAIN OUTBREAKS. ASSAYS HAVE BEEN TAILORED TO MANY DISEASES, ORGANISMS AND SAMPLE TYPES, INCLUDING MRSA, TUBERCULOSIS, KLEB, E COLI AND STAPHYLOCOCCUS. THE DIVISION WORKS CLOSELY WITH ITS SISTER INSTITUTE AT NORTHERN ARIZONA UNIVERSITY, THE PATHOGEN AND MICROBIOME INSTITUTE, AS WELL AS WITH A NUMBER OF OTHER COLLABORATORS LOCALLY, NATIONALLY AND GLOBALLY. THE DIVISION HAS BEEN INSTRUMENTAL IN SOLVING NUMEROUS DISEASE OUTBREAKS AROUND THE WORLD, HAS GENERATED MULTIPLE INVENTIONS AND HAS LICENSED OUT INTELLECTUAL PROPERTY TO GOVERNMENTS AND BIOTECH COMPANIES. Form 990, Part III, Line 4c INTEGRATED CANCER THE DIVISION OF INTEGRATED CANCER GENOMICS (ICG) IS UTILIZING STATE-OF-THE-ART MOLECULAR TECHNOLOGIES TO UNCOVER THE MULTIPLE DIMENSIONS OF MOLECULAR CHANGES THAT OCCUR IN CANCER, AND INTEGRATE THESE DATASETS TO CAPTURE A HIGH-RESOLUTION IMAGE OF THE TUMOR MOLECULAR LANDSCAPE. AMONG ICG FACULTY, THE DIVISION BOASTS AN AMAZING ARRAY OF COMPETENCIES INCLUDING GENOMIC PROFILING USING VARIOUS TECHNOLOGIES THAT INCLUDE NEXT-GENERATION SEQUENCING INCLUDING SINGLE-CELL, EPIGENETICS, NEOANTIGEN ANALYSIS, CANCER CELL BIOLOGY AND BIOINFORMATICS. ACROSS THE VARIOUS LABORATORIES, WE STUDY A MULTITUDE OF ADULT AND PEDIATRIC CANCERS, TRYING TO UNDERSTAND THE EVENTS THAT DRIVE CANCER PROGRESSION FROM PRIMARY TO ADVANCED METASTATIC DISEASE IN ADDITION TO UNDERSTANDING WHY AND HOW CANCER AFFECTS INDIVIDUALS FROM DIFFERENT ETHNICITIES AND ANCESTRAL BACKGROUNDS. ICG FACULTY ARE ALSO INVOLVED IN APPLYING HIGH-RESOLUTION GENOMIC TECHNOLOGIES TO PATIENT SAMPLES IN REAL TIME, DURING CLINICAL MANAGEMENT, TO ASSIST ONCOLOGISTS IN MAKING THERAPEUTIC RECOMMENDATIONS FOR CANCER PATIENTS. ICG IS DIRECTLY AIMING ITS EFFORTS TO DRIVE EARLIER DIAGNOSTICS AND SMARTER TREATMENTS TOWARDS PATIENTS. Form 990, Part III, Line 1 THE TRANSLATIONAL GENOMICS RESEARCH INSTITUTE (TGEN) IS A NONPROFIT BIOMEDICAL RESEARCH INSTITUTE FOCUSED ON DEVELOPING EARLIER AND SMARTER TREATMENTS BY EMPLOYING INNOVATIVE ADVANCES ARISING FROM THE HUMAN GENOME PROJECT AND APPLYING THEM TO THE DEVELOPMENT OF DIAGNOSTICS, PROGNOSTICS AND THERAPIES FOR CANCER, NEUROLOGICAL DISORDERS, DIABETES AND OTHER COMPLEX DISEASES. Form 990, Part III, Line 4d Description of other program services (Expenses $ 31,824,392 including grants of $ 328,217)(Revenue $ 6,467,880) JUNE 26, 2022, MARKED THE 20TH ANNIVERSARY OF TGEN'S LAUNCH. WHAT BEGAN WITH TEMPORARY LABORATORY AND ADMINISTRATIVE SPACE AND A HANDFUL OF EMPLOYEES HAS GROWN INTO AN INSTITUTE WITH OVER 350 EMPLOYEES, MULTIPLE LOCATIONS, HUNDREDS OF COLLABORATIONS AROUND THE WORLD, NUMEROUS GROUNDBREAKING STUDIES, AND NEARLY 20 SPIN-OUT COMPANIES. TODAY, OUR CAPACITY TO UNDERSTAND AND LEVERAGE INFORMATION FROM THE HUMAN GENOME HAS NEVER BEEN GREATER. TGEN'S ABILITY TO BRING EMERGING NEW METHODS FOR INTERROGATING A PATIENT'S GENOME INTO THE CLINICAL CARE OF PATIENTS, THE REVOLUTION IN FASTER AND LOWER-COST WAYS OF CANCER DETECTION AND THE PATHS THAT REACH THE URBAN, THE RURAL AND MORE DIVERSE POPULATIONS, HAS NEVER BEEN GREATER. THE SEQUENCE COST PER-PATIENT OVER THE PAST DECADE HAS DROPPED 100-FOLD. THIS MEANS TGEN CAN SEQUENCE MORE PATIENTS, OR SEQUENCE A PATIENT AGAIN, TO UNDERSTAND HOW THEIR DISEASE IS PROGRESSING. AS PART OF A NATIONAL HEALTH SYSTEM, THIS HELPS DRIVE RESEARCH DISCOVERY, NEW METHODS FOR EARLY DETECTION, AND MORE CLINICAL TRIALS. SEQUENCING ACCURACY HAS ALSO IMPROVED 100-FOLD. THIS INCREASED ACCURACY MEANS TGEN CAN DETECT CANCER EARLIER - PERHAPS IN ITS INFANCY - WHICH LEADS TO IMPROVED SCREENING, POST-TREATMENT MONITORING AND BIOPSIES WITH A LOW PERCENTAGE OF TUMOR PRESENT. THIS ALSO ALLOWS US TO EXPAND GENOMIC TESTING INTO MORE CANCER TYPES. WE'RE ALSO CREATING BETTER REFERENCE GENOMES, ESPECIALLY IN UNDERSERVED POPULATIONS. HAVING BETTER REFERENCES MEANS A BETTER UNDERSTANDING OF WHICH CHANGES IN THE GENOME ARE SIGNIFICANT AND TO WHICH POPULATION. Form 990, Part VI, Line 6 Classes of members or stockholders THE SOLE CORPORATE MEMBER OF TGEN IS CITY OF HOPE. Form 990, Part VI, Line 7a Members or stockholders electing members of governing body City of Hope, as the sole corporate member of Tgen, appoints Tgen's Board of Directors. Form 990, Part VI, Line 7b Decisions requiring approval by members or stockholders CERTAIN ACTIONS MAY NOT BE UNDERTAKEN WITHOUT THE PRIOR WRITTEN APPROVAL OF THE SOLE CORPORATE MEMBER, CITY OF HOPE, AS SPECIFIED IN THE GOVERNING DOCUMENTS OF TGEN, ON BEHALF OF ITSELF OR CERTAIN AFFILIATES, BORROW OR LEND MONEY OR PLEDGE PROPERTY AS SECURITY; FIX COMPENSATION FOR DIRECTORS; CHANGE THE NUMBER OF VOTING DIRECTORS; ASSIGN, TRANSFER, PLEDGE, COMPROMISE OR RELEASE CERTAIN CLAIMS OR DEBTS; COMMENCE ASSIGNMENT FOR THE BENEFIT OF CREDITORS, PETITION FOR REORGANIZATION OR SIMILAR RELIEF OR ACTION; ACQUIRE, PURCHASE, DEVELOP, MATERIALLY IMPROVE, SELL, LEASE, OR MORTGAGE CORPORATE REAL ESTATE; MERGE, DISSOLVE OR SELL ALL OR SUBSTANTIALLY ALL ASSETS; ADOPT BUDGETS, STRATEGIC PLANS OR MATERIAL CHANGES TO OPERATIONS; FORM AFFILIATES OR MAKE BUSINESS INVESTMENTS; ADOPT, REPEAL OR AMEND KEY GOVERNING DOCUMENTS; EXERCISE CERTAIN GOVERNANCE RIGHTS; INCUR LIABILITIES OR CONTRACT OTHER THAN FOR FAIR CONSIDERATION AND IN THE ORDINARY COURSE OF BUSINESS. Form 990, Part VI, Line 8b Documentation of meetings held by committees of governing body There are no committees with the authority to act on behalf of the governing body. Form 990, Part VI, Line 11b Review of form 990 by governing body THE FORM 990 IS PREPARED BY AN OUTSIDE ACCOUNTING FIRM BASED ON INFORMATION PROVIDED BY THE TGEN FINANCE DEPARTMENT. THE FORM 990 IS THEN REVIEWED BY THE FINANCE DEPARTMENT, OTHER MEMBERS OF MANAGEMENT AND THE AUDIT AND COMPLIANCE COMMITTEE OF THE CITY OF HOPE. THE FORM 990 IS POSTED ON THE BOARD WEBSITE FOR BOARD REVIEW PRIOR TO FILING WITH THE IRS. Form 990, Part VI, Line 12c Conflict of interest policy TGEN DISTRIBUTES A CONFLICT OF INTEREST QUESTIONNAIRE ANNUALLY TO ALL DIRECTOR LEVEL POSITIONS AND ABOVE, IN ADDITION TO ANY OFFICERS AND KEY EMPLOYEES DESIGNATED BY THE CONFLICT OF INTEREST COMMITTEE. THE QUESTIONNAIRES ARE REVIEWED BY TGEN'S FINANCE DEPARTMENT AND THE OFFICE OF RESEARCH COMPLIANCE. THOSE EMPLOYEES WITH CONFLICTS ARE FURTHER REVIEWED BY THE CONFLICT OF INTEREST COMMITTEE TO ENSURE AN APPROPRIATE PLAN IS SET FORTH. UPDATES TO THE LIST ARE HANDLED ON AN AS-NEEDED BASIS, BASED ON CONTRACT REVIEWS AND EMPLOYEE INFORMATION. Form 990, Part VI, Line 15a Process to establish compensation of top management official THE EXECUTIVE COMPENSATION AND GOVERNANCE COMMITTEE OF THE MEMBER SHALL BE THE EXECUTIVE COMPENSATION COMMITTEE OF TGEN. THE COMPENSATION REVIEW PROCESS WAS LAST COMPLETED IN 2022. Form 990, Part VI, Line 15b Process to establish compensation of other employees THE EXECUTIVE COMPENSATION AND GOVERNANCE COMMITTEE OF THE MEMBER SHALL BE THE EXECUTIVE COMPENSATION COMMITTEE OF TGEN. THE COMPENSATION REVIEW PROCESS WAS LAST COMPLETED IN 2022. Form 990, Part VI, Line 19 Required documents available to the public TGEN'S ARTICLES OF INCORPORATION ARE AVAILABLE TO THE PUBLIC THROUGH THE ARIZONA CORPORATION COMMISSION. TGEN'S AUDITED FINANCIAL STATEMENTS AND ITS CONFLICT OF INTEREST POLICIES ARE AVAILABLE BY WRITTEN REQUEST MADE TO THE CFO AND CONFLICT OF INTEREST DIRECTOR, RESPECTIVELY. TGEN'S BYLAWS ARE NOT MADE AVAILABLE TO THE PUBLIC. Form 990, Part IX, Line 11g Other Fees CONSORTIUM/CONTRACTUAL - Total Expense: 2102316, Program Service Expense: 2102316, Management and General Expenses: 0, Fundraising Expenses: 0; OUTSIDE RESEARCH SERVICES - Total Expense: 3136734, Program Service Expense: 2835066, Management and General Expenses: 301668, Fundraising Expenses: 0; CONSULTING - Total Expense: 2714973, Program Service Expense: 1308952, Management and General Expenses: 1406021, Fundraising Expenses: 0; TEMPORARY SERVICES - Total Expense: 154541, Program Service Expense: 357, Management and General Expenses: 154184, Fundraising Expenses: 0; THE CENTER FOR TRANS DRUG DEVELOPMENT 445 N 5TH STREET SUITE 600 PHOENIX AZ 85004 432047329 DRUG DEVEL AZ TGAM LLC TGEN ACCELERATORS LLC 445 N 5TH STREET SUITE 600 PHOENIX AZ 85004 753065445 GENOMICS AZ TGEN TRANSLATIONAL SYSTEMS LLC 445 N 5TH STREET SUITE 600 PHOENIX AZ 85004 461309498 ADV RESEARCH AZ TGEN VIDIUM LLC 445 N 5TH STREET SUITE 600 PHOENIX AZ 85004 843319906 ANIMAL DIAG AZ 500681 824758 TGEN TGEN HEALTH VENTURES LLC 445 N 5TH STREET SUITE 600 PHOENIX AZ 85004 464520712 HEALTHCARE AZ TGEN DROPWISE LLC 445 N 5TH STREET SUITE 600 PHOENIX AZ 85004 811959403 RESEARCH AZ 100000 7740 TGAM LLC ID ORIGINS LLC 445 N 5TH STREET SUITE 600 PHOENIX AZ 85004 753065445 TECH TRANSFER DE TGAM LLC PROFERO LLC 445 N 5TH STREET SUITE 600 PHOENIX AZ 85004 753065445 LICENSING DE TGEN METRICBIO LLC 445 N 5TH STREET SUITE 600 PHOENIX AZ 85004 814455083 RESEARCH AZ 10233 TGEN PMED MANAGEMENT LLC 445 N 5TH STREET SUITE 600 PHOENIX AZ 85004 383922888 HEALTHCARE AZ TGEN HV LLC PRECISION MEDICINE FACILITIES LLC 445 N 5TH STREET SUITE 600 PHOENIX AZ 85004 822560090 REAL ESTATE AZ 7868085 44547161 TGEN TGEN RESEARCH INSTITUTE FOUNDATION 445 N 5TH STREET SUITE 600 PHOENIX AZ 85004 331092191 FUNDRAISING AZ 501(c)(3) 7 TGEN true CITY OF HOPE 1500 EAST DUARTE ROAD DUARTE CA 91010 953435919 FUNDRAISING CA 501(c)(3) 7 NA false CITY OF HOPE NATIONAL MEDICAL CENTER 1500 EAST DUARTE ROAD DUARTE CA 91010 951683875 HOSPITAL CA 501(c)(3) 3 CITY OF HOPE true BECKMAN RESEARCH INSTITUTE 1450 EAST DUARTE ROAD DUARTE CA 91010 953432210 RESEARCH CA 501(c)(3) 4 CITY OF HOPE true CITY OF HOPE MEDICAL FOUNDATION 1500 EAST DUARTE ROAD DUARTE CA 91010 272803222 HEALTHCARE CA 501(c)(3) 3 CITY OF HOPE true COH HoldCo Inc 1500 East Duarte Road Duarte CA 91010 873651176 Support DE 501(c)(3) Type III-FI City of Hope true SOUTHERN CA RADIATION ONCOLOGY 1500 EAST DUARTE ROAD DUARTE CA 91010 364887584 MGMT SERVICES CA NA N/A false false ACCESSHOPE LLC 1500 EAST DUARTE ROAD DUARTE CA 91010 842818450 ONCOLOGY SUPPORT CA NA N/A false false COH HOLDCO INC (CONVERTED TO TAX-EXEMPT ON 93022) 1500 EAST DUARTE ROAD DUARTE CA 91010 873651176 SUPPORT DE CITY OF HOPE C Corporation true false true true false false false false false false false false true false true true false true false false TGEN RESEARCH INSTITUTE FOUNDATION C 11063484 ACTUAL COST CITY OF HOPE NATIONAL MEDICAL CENTER O 1219508 ACTUAL COST TGEN RESEARCH INSTITUTE FOUNDATION Q 1496868 ACTUAL COST CITY OF HOPE NATIONAL MEDICAL CENTER B 328217 Actual Cost